Braveheart Bio (NASDAQ:BRVE) Upgraded by Wall Street Zen to Hold Rating

by · The Markets Daily

Wall Street Zen upgraded shares of Braveheart Bio (NASDAQ:BRVE – Free Report) to a hold rating in a research note released on Saturday morning.

Braveheart Bio Stock Up 4.1%

BRVE stock opened at $27.03 on Friday. Braveheart Bio has a one year low of $24.61 and a one year high of $32.00.

Insider Activity

In related news, major shareholder Growth Opportunities F. Forbion purchased 1,920,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $34,560,000.00. Following the completion of the purchase, the insider owned 11,640,546 shares in the company, valued at approximately $209,529,828. This represents a 19.75% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Viehbacher bought 83,333 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $18.00 per share, with a total value of $1,499,994.00. Following the completion of the transaction, the director owned 609,519 shares in the company, valued at approximately $10,971,342. This trade represents a 15.84% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 8,751,942 shares of company stock worth $157,534,956.

About Braveheart Bio

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

Featured Articles